Q1: What area of law does Mayo Collaborative Services v. Prometheus Laboratories, Inc. primarily address?
Patent Law (Intellectual Property)
Q2: What was the central legal issue in Mayo Collaborative Services v. Prometheus Laboratories, Inc.?
Are method claims that recite a natural correlation between metabolite levels and drug efficacy/toxicity patent-eligible under 35 U.S.C. § 101 when the additional claim steps consist of well-understood, routine, and conventional activity previously engaged in by those in the field?
Q3: What rule did the court apply?
Laws of nature, natural phenomena, and abstract ideas are not patentable under 35 U.S.C. § 101. To be patent-eligible, a claim that involves a law of nature must include additional elements that amount to significantly more than the law of nature itself—an inventive concept that transforms the claim into a patent-eligible application. Merely appending well-understood, routine, conventional activity (or post-solution activity) to a natural law does not suffice, nor does drafting the claim in method form with generic administration or measurement steps. The machine-or-transformation test is a useful clue but not determinative. Eligibility must be assessed to avoid disproportionately tying up (preempting) the use of the underlying natural law.
Q4: What was the court's holding?
No. The claims are not patent-eligible. They effectively claim a law of nature—the correlation between thiopurine metabolite levels and therapeutic efficacy/toxicity—and the additional steps of administering and determining metabolite levels are well-understood, routine, and conventional activities that do not supply an inventive concept. The Supreme Court reversed the Federal Circuit.
Q5: Why is Mayo Collaborative Services v. Prometheus Laboratories, Inc. significant?
Mayo crystallized the modern § 101 framework later formalized in Alice, introducing the requirement that claims reciting ineligible concepts must include an inventive concept—something significantly more than well-understood, routine, conventional activity. It reshaped patent strategy in life sciences, particularly for diagnostic methods, and led to the invalidation of numerous diagnostic and correlation-based patents (e.g., Ariosa v. Sequenom). For law students, Mayo is foundational to understanding eligibility analysis, the preemption rationale, how to integrate scientific discoveries into patentable applications, and the persistent tension between § 101 and other patentability requirements.